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8Carotid stenting versus endarterectomy in patients
undergoing reintervention after prior carotid
endarterectomy
Margriet Fokkema, MD,a Gert Jan de Borst, MD, PhD,b Brian W. Nolan, MD,c Ruby C. Lo, MD,a
Robert A. Cambria, MD,d Richard J. Powell, MD,c Frans L. Moll, MD, PhD,b and
Marc L. Schermerhorn, MD,a on behalf of the Vascular Study Group of New England, Boston, Mass; Utrecht,
The Netherlands; Lebanon, NH; and Bangor, Me
Background: Outcomes for patients undergoing intervention for restenosis after prior ipsilateral carotid endarterectomy
(CEA) in the era of carotid angioplasty and stenting (CAS) are unclear. We compared perioperative results and durability
of CAS vs CEA in patients with symptomatic or asymptomatic restenosis after prior CEA and investigated the risk of
reintervention compared with primary procedures.
Methods: Patients undergoing CAS and CEA for restenosis between January 2003 and March 2012 were identiﬁed within
the Vascular Study Group of New England (VSGNE) database. End points included any stroke, death or myocardial
infarction (MI) within 30 days, cranial nerve injury at discharge, and restenosis $70% at 1-year follow-up. Multivariable
logistic regression was done to identify whether prior ipsilateral CEA was an independent predictor for adverse outcome.
Results: Out of 9305 CEA procedures, 212 patients (2.3%) underwent redo CEA (36% symptomatic). Of 663 CAS
procedures, 220 patients (33%) underwent CAS after prior ipsilateral CEA (31% symptomatic). Demographics of patients
undergoing redo CEA were comparable to patients undergoing CAS after prior CEA. Stroke/death/MI rates were
statistically similar between redo CEA vs CAS after prior CEA in both asymptomatic (4.4% vs 3.3%; P [ .8) and
symptomatic patients (6.6% vs 5.8%; P [ 1.0). No signiﬁcant difference in restenosis $70% was identiﬁed between redo
CEA and CAS after prior CEA (5.2% vs 3.0%; P[ .5). Redo CEA vs primary CEA had increased stroke/death/MI rate in
both symptomatic (6.6% vs 2.3%; P[ .05) and asymptomatic patients 4.4% vs 1.7%; P[ .03). Prior ipsilateral CEA was
an independent predictor for stroke/death/MI among all patients undergoing CEA (odds ratio, 2.1; 95% conﬁdence
interval, 1.3-3.5). No difference in cranial nerve injury was identiﬁed between redo CEA and primary CEA (5.2% vs 4.7%;
P [ .8).
Conclusions: In the VSGNE, CEA and CAS showed statistically equivalent outcomes in asymptomatic and symptomatic
patients treated for restenosis after prior ipsilateral CEA. However, regardless of symptom status, the risk of reinter-
vention was increased compared with patients undergoing primary CEA. (J Vasc Surg 2014;59:8-15.)The reported incidence of restenosis after carotid end-
arterectomy (CEA) ranges from 6% to 15%, depending on
the duration of follow-up and its measurement criteria.1,2
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Trial (CREST) showed the clinical signiﬁcance of recurrent
stenosis$70%, with increased risk of ipsilateral stroke within
2 years of surgery.3 The management of restenotic lesions
remains unclear.4-6 Since redo-surgery after prior ipsilateral
CEA potentially leads to amore challenging operation, prior
CEA has been considered a ‘high-risk’ condition for CEA
with increased risk of cranial nerve injury (CNI) and other
local complications.7,8 Yet, only few studies also report an
increased stroke risk for redo CEA compared with primary
CEA.9,10 In patients for whom reintervention is indicated,
carotid angioplasty and stenting (CAS) might be a suitable
alternative to reoperation. CAS has been increasingly per-
formed in restenotic lesions after the Centers for Medicare
and Medicaid Services approved reimbursement for CAS
in patients with symptomatic restenosis after CEA.11 Rela-
tive safety has been shown in early results,12 but long-term
outcome remains undeﬁned.13 Few analyses have directly
compared outcomes of redo CEA vs CAS in patients with
restenosis after prior CEA.14-17 Most studies that reported
on outcome after CAS and/or CEA in restenotic lesions
have been limited to single-institution series with insufﬁ-
cient power to detect differences in outcome. Further, these
studies did not distinguish symptomatic from asymptomatic
Fig 1. Overview of study groups and outcome. (1) To compare
outcome between redo-carotid endarterectomy (CEA) and carotid
angioplasty and stenting (CAS) in patients undergoing restenosis
after prior ipsilateral CEA. (2) To investigate the risk of reinter-
vention compared with the primary intervention.
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beyond the perioperative period. In a recent study by the
Vascular Study Group of New England (VSGNE), a history
of prior ipsilateral CEA predicted stroke or death following
carotid revascularization.17 In the current study, we aimed
to further investigate this observation. Our primary goal
was to compare perioperative major adverse events and
1-year patency between redo CEA and CAS for patients
with restenosis after prior ipsilateral CEA, stratiﬁed by
symptom status. Secondly, we investigated the risk of rein-
tervention compared with primary procedures (Fig 1).
METHODS
Database. Data collected by the VSGNE were used
for this analysis. The VSGNE is a regional quality-improve-
ment initiative developed in 2002 and currently involves
over 180 physicians at 30 centers (14 academic, 16
community). Preoperative clinical characteristics, imaging
studies, operative outcome, and follow-up data are
collected and entered in the registry by trained nurses or
clinical data abstractors. Surgeons enter operative details.
Research analysts are blinded to patient, surgeon, and
hospital identity. Further details on this registry have been
published previously and are available at http://www.
vascularweb.org/regionalgroups/vsgne. VSGNE data have
been validated for completeness using audits of discharge
claims data from each participating institution.17 Addi-
tionally, we have not identiﬁed any mortality bias by cases
not initially captured.18
Patients. Our study sample included all patients in the
VSGNE registry who underwent CEA (between January
2003 and December 2011) or CAS (between July 2005
and March 2012). Patients undergoing CEA with
a concomitant coronary artery bypass grafting procedure
were excluded (n ¼ 221). If both the initial CEA proce-
dure and the reintervention (CAS or redo CEA) were re-
ported for one patient, the initial CEA was excluded (n ¼
52). In total, 9305 CEAs from 26 centers performed by
136 surgeons, and 663 CAS from 13 centers performed by
58 surgeons were available for analyses. Within this sample,
patients with a prior ipsilateral CEA in their medical history
were identiﬁed. This resulted in a “reintervention group”
of 432 patients including 212 redo CEAs and 220 CAS
and a “primary procedure group” of 9536 patients
including 9093 primary CEAs and 443 primary CAS
procedures. In those who underwent a third ipsilateral
carotid intervention (n ¼ 6), only the secondary interven-
tion after the initial CEA was included for analyses.
End points and measurements. Our primary end
points were any stroke, a composite of any stroke or death,
and a composite of stroke, death, or myocardial infarction
(MI) at 30 days postoperatively. Secondary end points
included restenosis $70% as assessed by duplex ultrasound
(DUS) during follow-up. In addition, CEA and CAS
speciﬁc perioperative outcomes were evaluated. For CEA,
these included any CNI (as assessed at discharge by
the operating surgeon), wound infection, and bleeding
needing reintervention. For CAS, these included technicalfailure, access site complications, and bradyarrhythmia
requiring treatment during the procedure.
The deﬁnition of stroke included ipsilateral or contra-
lateral major strokes (cortical, vertebrobasilar, or ocular
disability resulting in nonindependent living status, or
blindness) and ipsilateral or contralateral minor stroke
(other strokes not deﬁned as major). Neurologists did
not routinely examine patients postoperatively, although
this is part of the protocol for CAS at several of the partici-
pating institutions. MIs included clinical, electrocardio-
gram, and troponin-only MI. Indications for obtaining
postoperative troponin are institution dependent and vari-
able. Not all centers routinely screened all postoperative
patients for MI with troponin.
For the evaluation of restenosis, we studied patients
who had undergone DUS evaluation during follow-up.
Among CAS patients, we were able to analyze 376 patients
(56.7%) at a median follow-up of 254 days. Of the 287
patients (43.3%) without DUS information, 228 patients
(34.4%) underwent stenting procedures in 2011 or 2012
and had therefore not completed 1-year follow-up yet at
time of data analysis. The remaining missing 59 patients
(8.9%) were lost to follow-up, or they did not undergo
DUS imaging during follow-up. For CEA, 6189 patients
(67%) were available for restenosis analyses at a median
of 370 days. Of those without DUS information
(n ¼ 3116; 33.4%), 1256 patients (13.5%) had undergone
CEA in 2011 and had therefore not completed 1-year
follow-up. The remaining 1860 patients (20%) were lost
to follow-up or did not undergo DUS imaging at their
follow-up consult. Results for primary outcome were strat-
iﬁed by preoperative symptom status. Symptomatic patients
JOURNAL OF VASCULAR SURGERY
10 Fokkema et al January 2014were deﬁned as having an ipsilateral neurologic event,
including any hemispheric or ocular transient ischemic
attack, major or minor stroke preceding the intervention.
Statistical analysis. Patient characteristics and
outcome from patients who underwent redo CEA or
CAS after prior ipsilateral CEA were compared using c2 or
Fisher exact test for categorical variables and two-tailed
t-test for continuous variables. Within the CAS and CEA
group, patient characteristics and outcomes of reinterven-
tion were also compared with primary procedures.
Multivariable logistic regression was performed to eval-
uate whether prior ipsilateral CEA was predictive for
adverse outcome (stroke/death and stroke/death/MI)
following CEA. Candidate predictors were identiﬁed by
bivariate analysis and included in the multivariable model
if the P value was <.1 (Supplementary Table I, online
only). Backward stepwise selection was applied to generate
odds ratios (ORs) and corresponding 95% conﬁdence
intervals (CIs). The multivariable models were adjusted
for age and sex. Predicted probabilities for adverse
outcome were calculated based on the ﬁnal models. P
values of <.05 were considered signiﬁcant. SPSS v. 19.0
statistical software (IBM Corporation SPSS Statistics,
Armonk, NY) was used for statistical analyses.
RESULTS
Redo CEA vs CAS after prior CEA
Patient characteristics. Among patients who under-
went reintervention after prior ipsilateral CEA, preopera-
tive characteristics were comparable between redo CEA
and CAS (Table I). The mean age was 69 years in both
groups; 58.5% were men in the CEA group and 63.2% in
the CAS group. Furthermore, 36% of patients were
symptomatic undergoing redo CEA vs 31% undergoing
CAS (P ¼ .3). All symptomatic patients had$50% stenosis,
whereas in asymptomatic patients, 93% of patients under-
going redo CEA and 95% of CAS patients had high-grade
$70% stenosis. Chronic obstructive pulmonary disease
(COPD) was more common in the CEA group (32.5% vs
20% CAS; P <.01). A greater proportion of patients in the
CEA group were on preoperative antiplatelet therapy
(aspirin or clopidogrel). Time from initial CEA to rein-
tervention was available for 52 patients (26 CAS and 26
CEA). Median time interval to CEA was 36 months
compared with 17.5 months to CAS (P ¼ .08).
Outcomes. Among symptomatic patients, outcome
after CEA vs CAS did not differ signiﬁcantly; 30-day
stroke and stroke/death rate were 3.9% vs 4.4% (P ¼
1.0) and stroke/death/MI rate was 6.6% vs 5.8% (P ¼ 1.0)
(Table II). For asymptomatic patients, outcome after CEA
vs CAS was also statistically similar: 30-day stroke and
stroke/death were 2.9% vs 2.0% (P ¼ .7) and stroke/
death/MI rate was 4.4% vs 3.3% (P ¼ .8). Length of stay
after CEA was 2.2 days, compared with 1.9 days after CAS
(P ¼ .4). During follow-up, rate of restenosis $70% was
5.2% after CEA and 3.0% after CAS (OR, 0.6; 95% CI, 0.2-
2.0; P ¼ .5). Only one symptomatic lesion (ipsilateralstroke at 13 months) was identiﬁed in a patient who
underwent CAS.
Redo CEA vs primary CEA
Patient characteristics. Comparison of demographics
and patient characteristics showed that COPD, smoking
(current or prior), contralateral occlusion, and previous
coronary artery bypass grafting or percutaneous coronary
intervention were more common in patients undergoing
redo CEA compared with primary CEA. Eversion CEA
was more frequently used in primary procedures (9.8% vs
3.8% redo CEA; P < .01). Patching was more common
with redo CEA (96% vs 87% primary CEA; P < .01)
(Supplementary Table II, online only).
Outcomes. Among symptomatic patients undergoing
redo CEA vs primary CEA, 30-day stroke, stroke/death,
and stroke/death/MI rates were higher after redo CEA,
but not statistically different (stroke, 4.0% vs 1.5%; P ¼
.1; stroke/death, 4.0% vs 1.8%; P ¼ .2; and stroke/death/
MI, 6.6% vs 2.8%; P ¼ .07) (Table III). Asymptomatic
patients undergoing redo CEA compared with those
undergoing primary CEA had signiﬁcantly higher rates for
stroke (2.9% vs 0.8%; P ¼ .03), stroke/death (2.9% vs
0.9%; P ¼ .04), and stroke/death/MI (4.4% vs 1.7%; P ¼
.03). CNI at discharge was similar after primary CEA
(5.1%; n ¼ 470) and redo CEA (6.1%; n ¼ 13; P ¼ .8; OR,
1.2; 95% CI, 0.7-2.1). One wound infection (0.5%) was
seen after redo CEA vs 7 (0.1%) after primary procedure
(P ¼ .2); 1.4% (n ¼ 3) had bleeding complications after
redo CEA vs 1.0% (n ¼ 90) after primary CEA (P ¼ 1.0).
Restenosis $70% was statistically similar in patients
undergoing primary CEA compared with redo CEA (2.8%
vs 5.2%; P ¼ .2; OR, 1.7; 95% CI, 0.9-4.2).
CAS after prior CEA vs primary CAS
Patients who underwent primary CAS had more
medical comorbidities than patients undergoing CAS after
prior CEA, such as coronary artery disease, congestive
heart failure, COPD, and an abnormal stress test (data
not shown). No signiﬁcant difference in stroke or death
rate was identiﬁed for both symptomatic (4.4% vs 7.6%
primary CAS; P ¼ .6) and asymptomatic (2.0% vs 0.7%
primary CAS; P ¼ .4) patients. Technical failure (2.3% vs
1.8% primary CAS; P ¼ nonsigniﬁcant [NS]) and access
site complications (8.6% vs 5.9% primary CAS; P ¼ NS)
were statistically similar, whereas signiﬁcantly more patients
required treatment for bradyarrhythmias during primary
CAS compared with patients undergoing CAS after prior
CEA (27.4% [n ¼ 121] vs 12.8% [n ¼ 28]; P < .01).
Multivariable analyses
Among all patients undergoing CEA (symptomatic and
asymptomatic), redo CEA was an independent predictor
for 30-day stroke/death (OR, 2.6; 95% CI, 1.4-4.7;
P ¼ .002) and stroke/death/MI (OR, 2.1; 95% CI,
1.3-3.5; P ¼ .002) (Table IV). Other predictive factors
for stroke/death were age >80 years, symptomatic status,
hypertension, contralateral occlusion, and urgent
Table I. Demographics and patient characteristics of patients undergoing redo-carotid endarterectomy (CEA) or carotid
angioplasty and stenting (CAS) after prior ipsilateral CEA in the Vascular Study Group of New England (VSGNE)
Redo CEA (n ¼ 212), CAS after prior CEA (n ¼ 220),
P valueNo. (%) No. (%)
Mean age 6 SD, years 68.8 6 9.2 68.9 6 8.5 .4
Age >80 years 26 (12.3) 25 (11.4) .9
Sex .3
Male 124 (58.5) 139 (63.2)
Female 88 (41.5) 80 (36.4)
Race (nonwhite) 2 (0.9) 3 (1.4) 1
Ipsilateral symptoms 76 (35.9) 69 (31.4) .3
TIA 54 (25.5) 55 (25.0)
Stroke 22 (10.4) 14 (6.4)
Ipsilateral degree of ICA stenosis .5
<50% 7 (3.3) 3 (1.4)
50%-59% 5 (2.4) 5 (2.3)
60%-69% 7 (3.3) 6 (2.7)
70%-79% 37 (17.5) 29 (13.2)
$80% 151 (71.2) 174 (79.1)
Occluded 3 (1.4) 3 (1.4)
Symptomatic patients $50% stenosis 212 (100) 220 (100) 1
Asymptomatic patients $70% stenosis 197 (93.0) 209 (95.0) .4
Any smoke (prior or current) 191 (90.1) 188 (85.5) .2
Hypertension ($140/90 or history) 189 (89.2) 207 (94.1) .1
Diabetes (on medication) 70 (33.0) 70 (31.8) .8
Coronary artery disease 82 (38.7) 78 (35.5) .6
CABG/PCI 81 (38.2) 79 (35.9) .5
Congestive heart failure 19 (9.0) 22 (10.0) .7
COPD 69 (32.6) 44 (20.0) <.01
Antiplatelet therapy 192 (90.6) 213 (96.8) <.01
Statin 175 (82.5) 183 (83.2) .9
Stress test abnormal (MI or ischemia) 18 (8.5) 18 (8.2) .9
On dialysis 1 (0.5) 2 (0.9) 1
Creatinine (>1.78 mg/dL) 12 (5.7) 13 (5.9) .3
ASA 3 and 4 93 (43.9) 101 (45.9) .6
Contralateral occlusion 24 (12.1) 24 (11.5) 1
Urgent procedures 27 (12.7) 21 (9.5) .4
Prior radiation 107 (1.2)
Eversion CEA 8 (3.8)
One or more medical high-risk factor(s) 58 (26.4)
One or more anatomic high-risk factor(s) 141 (64.1)
Refused surgery 38 (17.3)
ASA, American Society of Anesthesiology; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; ICA, internal carotid artery;
MI, myocardial infarction; PCI, percutaneous coronary intervention; SD, standard deviation; TIA, transient ischemic attack.
P values of <.05 are in bold.
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protective. Other predictors for stroke/death/MI were
female sex, symptomatic status, hypertension, congestive
heart failure, contralateral occlusion, and urgent proce-
dures (<24 hours of admission). Patients undergoing
redo CEA vs primary CEA had a signiﬁcantly higher pre-
dicted adverse outcome, reﬂecting they are a higher-risk
population in the redo-group (Fig 2).
DISCUSSION
In a large regional database, CAS and redo CEA
revealed equivalent perioperative and 1-year outcomes in
both asymptomatic and symptomatic restenosis after prior
CEA. Adverse outcome of reintervention was increased
compared with primary CEA, regardless of symptom
status.The results of the current study indicate that patients
with symptomatic or asymptomatic restenosis after prior
CEA form a high-risk group for intervention, regardless
of revascularization procedure or symptom status. Despite
the increased risk compared with primary CEA, both CAS
and CEA proved to be suitable options to treat symptom-
atic patients with restenosis after prior CEA. In asymptom-
atic patients, the beneﬁt of intervention is less clear with
a stroke/death rate of 2.9% after CEA, which is the upper
limit acceptable for asymptomatic lesions based on societal
guidelines. For these patients, a nonoperative approach
with medical treatment might be considered to achieve
optimal long-term stroke prevention given that the natural
history of asymptomatic lesions seems generally benign and
some may regress over time.19 However, others have
shown increased stroke risk in patients with severe stenosis
Table III. Thirty-day outcome of patients undergoing primary carotid endarterectomy (CEA) vs redo CEA in the
Vascular Study Group of New England (VSGNE)
Primary CEA (n ¼ 3033), Redo CEA (n ¼ 76),
P value OR 95% CINo. (%) No. (%)
Symptomatic Stroke 46 (1.5) 3 (3.9) .12 2.6 0.8-8.6
Stroke/death 53 (1.7) 3 (3.9) .16 2.3 0.7-7.5
Stroke/death/MI 71 (2.3) 5 (6.6) .05 2.4 0.96-6.1
Primary CEA (n ¼ 6059),
No. (%)
Redo CEA (n ¼ 136),
No. (%)
Asymptomatic Stroke 49 (0.8) 4 (2.9) .03 3.7 1.3-10.5
Stroke/death 54 (0.9) 4 (2.9) .04 3.4 1.2-9.4
Stroke/death/MI 105 (1.7) 6 (4.4) .04 2.6 1.1-6.1
CI, Conﬁdence interval, MI, myocardial infarction; OR, odds ratio.
Table II. Thirty-day outcome of patients undergoing redo-carotid endarterectomy (CEA) and carotid angioplasty and
stenting (CAS ) after prior ipsilateral CEA in the Vascular Study Group of New England (VSGNE)
Redo CEA (n ¼ 76), CAS after prior CEA (n ¼ 69),
P value OR 95% CINo. (%) No. (%)
Symptomatic Stroke 3 (3.9) 3 (4.4) 1.0 1.1 0.2-5.7
Stroke/death 3 (3.9) 3 (4.4) 1.0 1.1 0.2-5.7
Stroke/death/MI 5 (6.6) 4 (5.8) 1.0 0.9 0.2-3.4
Redo CEA (n ¼ 136),
No. (%)
CAS after prior CEA (n ¼ 151),
No. (%)
Asymptomatic Stroke 4 (2.9) 3 (2.0) .7 0.7 0.2-3.0
Stroke/death 4 (2.9) 3 (2.0) .7 0.7 0.2-3.0
Stroke/death/MI 6 (4.4) 5 (3.3) .8 0.7 0.2-2.5
CI, Conﬁdence interval; MI, myocardial infarction; OR, odds ratio.
Table IV. Multivariable model for adverse outcome
among symptomatic and asymptomatic patients
undergoing carotid endarterectomy (CEA) (n ¼ 9305)
Stroke/death Stroke/death/MI
OR 95% CI P value OR 95% CI P value
Age >80 years 1.8 1.2-2.7 .004 - - -
Female sex - - - 1.4 1.1-1.9 .013
Ipsilateral symptoms 2.1 1.4-3.0 <.001 1.7 1.2-2.2 .001
Prior ipsilateral CEA 2.6 1.4-4.7 .002 2.1 1.3-3.5 .002
Hypertension 2.5 1.2-5.4 .020 1.8 1.0-3.0 .036
Congestive heart
failure
- - - 2.0 1.4-2.9 <.001
Antiplatelet therapy 0.5 0.3-0.9 .009 - - -
Contralateral
occlusion
2.4 1.4-4.0 .001 1.9 1.2-3.0 .003
Urgency 1.8 1.2-2.8 .008 1.6 1.1-2.2 .014
CI, Conﬁdence interval; MI, myocardial infarction; OR, odds ratio.
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warranted in this subset of patients.3,20
Few studies have reported an increased stroke risk after
redo CEA compared with primary CEA.9,10 Aburahmaet al’s study yielded an ipsilateral stroke rate of 4.8% (6/
124) after redo CEA, compared with 0.8% (2/265)
following primary intervention with ﬁve of six strokes in
the redo group happening in symptomatic patients.9 In
contrast, more recent studies did not detect a difference in
stroke rate compared with primary surgery and concluded
that redo CEA was as safe as primary CEA.21-23 However,
small sample size limited the ability to detect statistical
differences or to stratify patients by symptom status in
most of these series. Others have reported on outcome after
redo CEA in single-center cohorts without a control
group.24-30 While most of these studies reported “accept-
able” perioperative stroke/death rates (0%-4.6%, all
patients), several groups have reported an increased risk
for local complications such as nerve injury (4.6%-21%)
and wound hematoma (4.2%).7,8,20,30,31 We did not
identify an increased risk for CNI compared with
primary CEA, nor did we note an increased risk for other
local complications with redo-surgery in a much larger pop-
ulation. As illustrated by a greater predicted stroke or death
rate than was actually observed in the redo group, the
increased risk for reintervention was therefore indicative of
a high-risk population rather than a high-risk procedure.
Fig 2. Predicted and observed stroke or death rate of patients
undergoing primary carotid endarterectomy (CEA) and redo
CEA. Both predicted and observed rates were signiﬁcantly
different between primary CEA and redo CEA (P < .01).
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was increased, Centers for Medicare and Medicaid Services
approved reimbursement for CAS in patients with symp-
tomatic, severe (>70%) restenosis after CEA. This policy
was mainly based on the results of the Stenting and Angio-
plasty with Protection in Patients at High Risk for Endar-
terectomy (SAPPHIRE) trial, designed to compare CAS
vs CEA in a high-risk population.32,33 In SAPPHIRE,
the 30-day stroke, death, MI rate in the CEA arm was as
high as 9.8% (vs 4.8% CAS; P ¼ .09). The MI rate of
6.6% strongly inﬂuenced this composite end point. More-
over, the generalizability of this cohort may be limited, as
approximately 70% of the study population was asymptom-
atic and the study design lacked stratiﬁcation within the
various high-risk groups (only 22% had recurrent stenosis
after CEA). Despite controversy over the applicability of
the SAPPHIRE results and the classiﬁcation of “high-
risk,”7,34 CAS was increasingly performed and evaluated
in patients with restenotic lesions. The Society of Vascular
Surgery (SVS) Vascular Registry (VR) data indicated
a protective effect of CAS in restenotic lesions compared
with primary CAS, and this observation was supported by
a subanalysis in the current study.12,35 A combination of
a higher-risk population in the primary CAS group and
a supposedly more stable plaque in restenotic lesions
caused by intimal hyperplasia36 may explain these ﬁndings.
This hypothesis is further supported by the lower risk of
procedural bradycardia in CAS after prior CEA, which
has also been previously shown.37 Our results suggested
that patients undergoing CAS after redo CEA were treated
for intimal hyperplasia rather than “late” restenosis
(>24 months) through progression of atherosclerotic
restenosis. Yet, the reported risk for 30-day stroke/
death/MI after CAS in restenotic lesions is still relativelyhigh in both asymptomatic (SVS VR, 3.5% and VSGNE,
3.3% [current analysis]) and symptomatic patients (SVS
VR, 6.7% and VSGNE, 5.8% [current analysis]) and not
superior to redo CEA.35 Long-term results after CAS
have not been thoroughly discussed in the current litera-
ture.13,38 Our ﬁndings indicate that rate of restenosis
$70% after 1 year is similar after CAS and CEA (3.0% vs
5.2%; NS). The vast majority of lesions remained asymp-
tomatic without a need for reintervention.
Few other groups have attempted to compare CAS and
CEA directly in patients with restenosis after prior CEA. In
a series of 83 patients, Aburahma et al31 reported increased
30-day stroke rates after CAS compared with CEA (16% vs
2.4%) and >50% in stent restenosis at 6 months, as deﬁned
by duplex ultrasound. In a later report comprising 192
patients (72 redo CEA and 120 CAS), the same group
did not detect any differences in 30-day stroke rate between
redo CEA and CAS (3% vs 1%; P ¼ .6), whereas the
increased risk for restenosis after CAS (mean follow-up
time of 2 years) persisted.15 Several studies have, however,
shown elevated sonographic velocities after stenting in the
absence of angiographically proven restenosis, which might
have caused increased rates of restenosis greater than 50%
after CAS.39 Two other groups showed equivalent outcome
between CAS and CEA albeit with smaller numbers.14,16
Nolan et al using VSGNE data sought to compare real-
world outcomes of CAS and CEA and found that a history
of prior ipsilateral CEA was an independent risk factor for
stroke or death in a model including all patients undergoing
CAS and CEA.17 This observation prompted us to further
stratify this cohort using a larger number of patients. While
primary CEA in symptomatic patients has proven to be
beneﬁcial over CAS, patients with symptomatic recur-
rent stenosis do equally well with CAS. Similar predictors
for adverse outcome were previously shown in the
VSGNE.17,40 Although age >80 years was associated with
stroke and death, female sex and congestive heart failure
were predictive for stroke/death/MI. Preoperative antipla-
telet therapy was protective for stroke and death but was not
associated with stroke/death/MI.
The results of this study must be interpreted in the
context of its design including the limitations of the data-
set. The VSGNE does not record the duration from
primary CEA to secondary intervention; however, we
were able to identify this time interval for several patients
who also underwent their primary CEA procedure in the
VSGNE. We are also not aware of the reasons for interven-
tion in patients with asymptomatic lesions <70%. Report-
ing bias is inherent to any registry-based study and
potentially leads to under-reporting of events. The low
stroke rate in the VSGNE compared with randomized
controlled trials such as CREST is likely in part caused by
the absence of a routine postoperative evaluation by
a neurologist. However, it seems unlikely that there was
bias in the reporting of events between CAS and CEA,
patients with and without prior CEA, or symptomatic
and asymptomatic patients. Furthermore, we used the
Social Security Death Index to ensure that all deaths
JOURNAL OF VASCULAR SURGERY
14 Fokkema et al January 2014were captured in our dataset. The lack of a standard
protocol to identify postoperative MI might have led to
lower rates compared with the randomized controlled
trials. Furthermore, the relatively low event rate after revas-
cularization procedures, particularly in the reintervention
groups, may have resulted in a type II error limiting our
ability to identify signiﬁcant differences. However, this is
the largest comparison to date of CAS vs redo CEA in
patients with restenosis after prior CEA, and we were
able to quantify the potential effect size and direction
among these patients, stratiﬁed for symptom status. Also,
follow-up length was limited at a median of 1 year. Lastly,
the duplex criteria were determined at each individual
center and are, thus, not uniform across the VSGNE.
Nonetheless, all the vascular laboratories in the VSGNE
centers are certiﬁed by the Intersocietal Commission for
the Accreditation of Vascular Laboratories.1 These factors
should be considered while interpreting our results on
restenosis.
In conclusion, we found that in a large regional quality
improvement registry reﬂecting real-world outcome,
patients undergoing reintervention after prior CEA are at
increased risk for adverse events, regardless of procedure.
For patients presenting with symptomatic recurrent carotid
artery stenosis, both CAS and CEA are suitable options.
For asymptomatic patients, the risk and beneﬁts of inter-
vention should be carefully weighed for individual patients.
Future work should focus on identifying those asymptom-
atic lesions that will eventually become symptomatic and
which asymptomatic patients have increased risk for perio-
perative adverse outcome.
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Supplementary Table I (online only). Bivariate associations of preoperative patient characteristics with adverse
outcome in symptomatic and asymptomatic patients undergoing carotid endarterectomy (CEA) (n ¼ 9305)
Stroke/death Stroke/death/MI
OR 95% CI P OR 95% CI P
Age >80 years 1.9 1.3-2.9 <.01 1.4 1.02-2.0 .049
Sex (male vs female) 1.1 0.8-1.7 .50 1.3 1.0-1.8 .05
Race (non-white) 1 0.9-1.01 .27 0.3 0.04-2.1 .26
Ipsilateral symptoms 1.9 1.4-2.9 <.01 1.7 1.2-2.2 <.01
Prior ipsilateral CEA 2.9 1.3-6.2 .02 2.6 1.4-4.8 <.01
Any smoke (prior or current) 1 0.6-1.5 .82 1.2 0.8-1.7 .48
Hypertension 2.1 1.01-4.6 .04 1.7 1.03-3.0 .04
Diabetes 0.9 0.6-1.4 .84 1.3 0.97-1.7 .09
Coronary artery disease 0.9 0.6-1.3 .55 1.4 1.05-1.9 .03
CABG/PCI 0.8 0.5-1.2 .31 1 0.7-1.3 .94
Congestive heart failure 1.1 0.6-2.2 .73 2.1 1.4-3.1 <.01
COPD 1.4 0.96-2.2 .09 1.5 1.1-2.0 .01
Antiplatelet therapy 0.5 0.3-0.9 .02 0.7 0.5-1.1 .19
Statin 1 0.9-1.01 1 1 0.9-1.01 .43
Stress test abnormal (MI or ischemia) 1.1 0.5-2.3 .84 1.6 1.0-2.6 .06
Creatinine (>1.78 mg/dL) 0.8 0.3-2.0 .82 1.6 0.9-2.6 .11
ASA 3 and 4 1.6 0.6-4.5 .51 2.2 0.9-5.5 .09
Contralateral occlusion 2.3 1.3-4.1 <.01 1.9 1.2-3.0 <.01
Urgent procedures 2.7 1.7-4.1 <.01 2.1 1.5-3.0 <.01
ASA, American Society of Anesthesiology; CABG, coronary artery bypass grafting; CI, conﬁdence interval; COPD, chronic obstructive pulmonary disease;
ICA, internal carotid artery; MI, myocardial infarction; OR, odds ratio; PCI, percutaneous coronary intervention.
P values of <.05 are in bold.
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Supplementary Table II (online only). Demographics and patient characteristics of patients undergoing redo-carotid
endarterectomy (CEA) or primary CEA in the Vascular Study Group of New England (VSGNE)
Redo CEA (n ¼ 212), No. (%) Primary CEA (n ¼ 9093), No. (%) P value
Mean age 6 SD, years 68.8 6 9.2 69.7 6 9.4 .2
Age >80 years 26 (12.3) 1428 (15.6) .2
Sex .7
Male 124 (58.5) 5447 (59.9)
Female 88 (41.5) 3646 (40.1)
Race (non-white) 2 (0.9) 152 (1.7) .6
Ipsilateral symptoms 76 (35.8) 3033 (33.3) .5
TIA 54 (25.5) 2100 (23.1)
Stroke 22 (10.4) 933 (10.3)
Ipsilateral degree of ICA stenosis <.01
<50% 7 (3.3) 69 (0.8)
50%-59% 5 (2.4) 155 (1.7)
60%-69% 7 (3.3) 380 (4.2)
70%-79% 37 (17.5) 2043 (22.5)
$80% 151 (71.2) 6370 (70.2)
Occluded 3 (1.4) 59 (0.6)
Any Smoke (prior or current) 191 (90.1) 7232 (79.6) <.01
Hypertension ($40/90 or history) 189 (89.2) 7987 (87.9) .7
Diabetes (on medication) 70 (33.0) 2814 (31.0) .8
Coronary artery disease 82 (38.7) 2869 (31.5) .1
CABG/PCI 81 (38.2) 2862 (31.4) <.01
Congestive heart failure 19 (8.9) 712 (7.8) .8
COPD 69 (32.6) 2042 (22.4) <.01
Antiplatelet therapy 192 (90.6) 8212 (88.3) .8
Statin 175 (98.9) 7030 (98.8) .5
Stress test abnormal (MI or ischemia) 18 (8.5) 931 (10.2) .7
On dialysis 1 (0.5) 50 (0.5) .8
Creatinine (>1.78 mg/dL) 12 (5.7) 481 (5.5) .8
ASA 3 and 4 93 (43.8) 3628 (39.8) .5
Contralateral occlusion 24 (12.1) 521 (6.0) <.01
Urgent procedures 27 (12.7) 1029 (11.3) .5
Prior radiation 107 (1.2) 3 (1.4) .7
Eversion CEA 8 (3.8) 899 (9.8) <.01
Patch use 204 (96.2) 7868 (87.1) <.01
ASA, American Society of Anesthesiology; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; ICA, internal carotid artery;
n, number of patients; MI, myocardial infarction; PCI, percutaneous coronary intervention; SD, standard deviation; TIA, transient ischemic attack.
P values of <.05 are in bold.
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